3 results about "Neoplastic tissue" patented technology

The invention discloses a neutron beam dynamic regulation and control method and system in a BNCT process, and the method comprises the following steps: constructing a neutron beam-out regulation and control model, and obtaining a mapping relation between the intensity of a neutron beam and a neutron dose rate; dynamically monitoring the boron concentration of the tumor tissue and the boron concentration of the normal tissue to obtain a real-time T / N value; converting the T / N value into neutron beam intensity in real time, and substituting the neutron beam intensity into the neutron beam output regulation and control model to obtain a real-time neutron dose rate; comparing the obtained real-time neutron dose rate with a preset neutron dose rate, and if there is a difference between the real-time neutron dose rate and the preset neutron dose rate, adjusting neutron source parameters until the real-time neutron dose rate is consistent with the preset neutron dose rate; and the step S2 to the step S4 are repeated, and neutron beam dynamic regulation and control in the BNCT process are achieved. According to the invention, the technical problem that the neutron outgoing beam regulation and control precision and efficiency are low due to the fact that the real-time change of the boron concentration is not considered in the prior art can be solved.

A model for simulating a brain soft tissue affected by neoplasm has a first portion for simulating a healthy tissue and a second portion for simulating a neoplastic tissue. The first portion and the second portion have a composition including water, gelatin, glycerin and sorbitol. The content by weight of glycerin and sorbitol is predominant over the content by weight of gelatin. The first portion has a liquid dye and the second portion has at least one powdered pigment.

Bacteria with tumor-targeting capability express, surface displayed, secreted and / or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. The chimeric proteins may be protease sensitive and may optionally be further accompanied by co-expression of a secreted protease inhibitor as a separate molecule or as a fusion.